Nursing Considerations for HER2- positive Breast Cancer : The Role of Herceptin® (trastuzmab)

Nursing Programs OCC COS Faculty About HER2 + Breast Cancer

Please click on the Nurse Dinner Programs link below to review a schedule and register for a dinner program. These programs have been designed to meet the needs of RNs and APNs.

Please note this is a promotional program and no CEUs will be offered.

ť Nurse Dinner Programs

Indications
Adjuvant indications
Herceptin is indicated for adjuvant treatment of HER2-overexpressing node-positive or node-negative (ER/PR-negative or with one high-risk feature)
breast cancer:

As part of a treatment regimen containing doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel
With docetaxel and carboplatin
As a single agent following multi-modality anthracycline-based therapy

Metastatic indications
Herceptin is indicated:

In combination with paclitaxel for the first line treatment of HER2 overexpressing metastatic breast cancer
As a single agent for treatment of HER2 overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease

Boxed WARNINGS and Additional Important Safety Information Herceptin administration can result in sub-clinical and clinical cardiac failure manifesting as congestive heart failure and decreased left ventricular ejection fraction. Serious infusion reactions and pulmonary toxicity have occurred; fatal infusion reactions have been reported. Exacerbation of chemotherapy-induced neutropenia has also occurred. The most common adverse reactions associated with Herceptin use were fever, nausea, vomiting, infusion reactions, diarrhea, infections, increased cough, headache, fatigue, dyspnea, rash, neutropenia, anemia, and myalgia.

Please click here for full prescribing information for Boxed WARNINGS and additional important safety information.

8377105